Opendata, web and dolomites


"CORolla® - a disruptive ""spring like"" metallic device for permanent treatment of diastolic heart failure."

Total Cost €


EC-Contrib. €






 CORolla project word cloud

Explore the words cloud of the CORolla project. It provides you a very rough idea of what is the project "CORolla" about.

congestive    topcat    ejection    start    families    time    shunting    invasive    health    ventricular    contraction    market    corolla    perfectly    frame    effect    augmentation    reg    interatrial    million    inside    ec    2021    treat    vision    older    company    trajectory    total    globally    minimally    systole       heart    sales    trials    drugs    social    animals    sme    complete    instrumental    corassist    fraction    left    planning    spring    energy    life    annually    accounting    ago    aligns    65    metallic    national    aging    economic    device    hfpef    individuals       threatening    treatment    filling    25    though    paragon    introduces    instrument    first    financial    cardiovascular    women    expanding    diastole    patients    prevalence    people    procedure    harnesses    releases    function    impaired    clinical    occurs    representing    hf    internal    validation    self    humans    diastolic    dynamics    19    preserved    solution    world    manages    population    augment    trial    needing    form    elastic    grant    implanted    more    relaxation   

Project "CORolla" data sheet

The following table provides information about the project.


Organization address
address: 114TH MORIYA AVE
city: HAIFA
postcode: 3461805
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-02-28


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CORASSIST CARDIOVASCULAR LTD IL (HAIFA) coordinator 50˙000.00


 Project objective

Heart Failure with preserved ejection fraction (HFpEF) is a life-threatening form of congestive heart failure condition annually affecting more than 25 million people globally. HFpEF occurs commonly in older individuals and has higher prevalence in women. As the European population is aging (over 65 accounting for 19.2% of the total European population, 2.4% more than 10 years ago), HFpEF will affect more and more people, representing significant economic and social challenge for the patients, their families and National Health Systems.

Currently there is no solution on the market for such heart failure condition. Though the effect of some drugs used in the treatment of HF with reduced ejection fraction are currently studied for HFpEF in large clinical trials (e.g. PARAGON-HF Trial, TOPCAT Study), a new approach based on the left interatrial shunting is needed.

The CorAssist introduces a “spring-like” metallic device, CORolla® for augmentation of diastolic function of the heart. The CORolla® is implanted inside the left ventricular of the heart in a minimally invasive procedure. The self-expanding, internal device harnesses the elastic energy during systole (contraction) state and releases it during diastole (relaxation) in order to augment dynamics of left ventricular relaxation and filling. CORolla® manages to impact directly and improve the impaired diastolic function, needing only one-time procedure.

CorAssist Cardiovascular has the vision to become the first company in the world to treat HFpEF. The EC grant is instrumental to this ambitious goal and company’s growth trajectory. Following a very promising validation in animals and humans, the company is planning to start first sales of CORolla® by the end of 2021.The SME Instrument project perfectly aligns with this objective, as it would provide the company with the financial resources necessary to complete the clinical study within the planned time-frame.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COROLLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COROLLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

HUD (2018)


Read More